Bulk drug substances used in compounding
However, Tat-BECN1 treatment delayed the onset of AA in the C3H/HeJ mouse model [114]
HGH Fragment 176-191 operates on the principle of enhanced lipolysis, effectively mimicking the fat-burning domain of human growth hormone without its insulin-modulating effects
In proof-of-concept studies, NNMT inhibitors (NNMTis) have demonstrated promise as potential treatments for obesity and obesity-related metabolic comorbidities (e.g., T2D, fatty liver) 8,9,13
Unlike semaglutide, tirzepatide targets both GLP-1 and GIP (gastric inhibitory polypeptide) receptors, enhancing fat metabolism and insulin sensitivity
AOD-9604 is not an FDA-approved drug